24 May 2019 - - Canadian contract research organisation Altasciences has been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency, the company said.

Altasciences will conduct the required Safety Testing, all IND-enabling studies (non-GLP and GLP), the necessary Phase I clinical trials, and associated bioanalytical analysis.

For over 25 years, Altasciences has been helping sponsors move from one key milestone to the next with the goal of helping them make informed, faster and more complete early phase drug development decisions.

Altasciences' full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management -- all of which can be tailored to specific sponsor requirements.

Altasciences is a mid-size contract research organisation offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept.